Genomic and nongenomic effects of glucocorticoids - PubMed (original) (raw)

Review

doi: 10.1038/ncprheum0898. Epub 2008 Sep 2.

Affiliations

• PMID: 18762788
• DOI: 10.1038/ncprheum0898

Review

Genomic and nongenomic effects of glucocorticoids

Cindy Stahn et al. Nat Clin Pract Rheumatol. 2008 Oct.

Abstract

The strong anti-inflammatory and immunosuppressive effects of glucocorticoids are mediated primarily by the cytosolic glucocorticoid receptors. These receptors are members of the steroid hormone receptor family, a superfamily of ligand-inducible transcription factors, and exert genomic effects that can result in increased expression of regulatory-including anti-inflammatory-proteins (transactivation), or decreased production of proinflammatory proteins (transrepression). Transactivation is thought to be responsible for numerous adverse effects of glucocorticoids; transrepression is thought to be responsible for many of the clinically desirable anti-inflammatory and immunosuppressive effects of glucocorticoids. Optimized glucocorticoids, such as selective glucocorticoid receptor agonists, are being developed to try to minimize the adverse effects many patients experience. Glucocorticoids also exert their effects via rapid, nongenomic mechanisms that can be classified as involving nonspecific interactions of glucocorticoids with cellular membranes, nongenomic effects that are mediated by cytosolic glucocorticoid receptors, or specific interactions with membrane-bound glucocorticoid receptors. Increased understanding of these mechanisms of glucocorticoid action could enable the development of novel drugs with which to treat patients with inflammatory and autoimmune disease.

PubMed Disclaimer

Similar articles

• Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
  Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Stahn C, et al. Mol Cell Endocrinol. 2007 Sep 15;275(1-2):71-8. doi: 10.1016/j.mce.2007.05.019. Epub 2007 Jun 2. Mol Cell Endocrinol. 2007. PMID: 17630118 Review.
• Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands.
  Löwenberg M, Stahn C, Hommes DW, Buttgereit F. Löwenberg M, et al. Steroids. 2008 Oct;73(9-10):1025-9. doi: 10.1016/j.steroids.2007.12.002. Epub 2007 Dec 14. Steroids. 2008. PMID: 18221974 Review.
• Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
  Schäcke H, Berger M, Rehwinkel H, Asadullah K. Schäcke H, et al. Mol Cell Endocrinol. 2007 Sep 15;275(1-2):109-17. doi: 10.1016/j.mce.2007.05.014. Epub 2007 May 31. Mol Cell Endocrinol. 2007. PMID: 17630119 Review.
• Optimized glucocorticoid therapy: teaching old drugs new tricks.
  Strehl C, Buttgereit F. Strehl C, et al. Mol Cell Endocrinol. 2013 Nov 5;380(1-2):32-40. doi: 10.1016/j.mce.2013.01.026. Epub 2013 Feb 8. Mol Cell Endocrinol. 2013. PMID: 23403055 Review.
• [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
  Huisman AM, Jacobs JW, Buttgereit F, Bijlsma JW. Huisman AM, et al. Ned Tijdschr Geneeskd. 2006 Mar 4;150(9):476-80. Ned Tijdschr Geneeskd. 2006. PMID: 16553045 Review. Dutch.

Cited by

• Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity.
  Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Lee MJ, et al. Biochim Biophys Acta. 2014 Mar;1842(3):473-81. doi: 10.1016/j.bbadis.2013.05.029. Epub 2013 Jun 2. Biochim Biophys Acta. 2014. PMID: 23735216 Free PMC article. Review.
• Dose and latency effects of leucine supplementation in modulating glucose homeostasis: opposite effects in healthy and glucocorticoid-induced insulin-resistance states.
  Zanchi NE, Guimarães-Ferreira L, de Siqueira-Filho MA, Felitti V, Nicastro H, Bueno C, Lira FS, Naimo MA, Campos-Ferraz P, Nunes MT, Seelaender M, de Oliveira Carvalho CR, Blachier F, Lancha AH. Zanchi NE, et al. Nutrients. 2012 Nov 27;4(12):1851-67. doi: 10.3390/nu4121851. Nutrients. 2012. PMID: 23363994 Free PMC article.
• The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.
  Cutolo M, Spies CM, Buttgereit F, Paolino S, Pizzorni C. Cutolo M, et al. Arthritis Res Ther. 2014 Nov 13;16 Suppl 2(Suppl 2):S1. doi: 10.1186/ar4685. Arthritis Res Ther. 2014. PMID: 25608624 Free PMC article. Review.
• Early Treatment of Multisystem Inflammatory Syndrome in Children.
  Jonat B, Geneslaw AS, Capone CA, Shah S, Bartucca L, Sewell TB, Acker KP, Mitchell E, Cheung EW. Jonat B, et al. Pediatrics. 2023 Sep 1;152(3):e2023061297. doi: 10.1542/peds.2023-061297. Pediatrics. 2023. PMID: 37534417 Free PMC article.
• Glucocorticoid sensitivity in health and disease.
  Quax RA, Manenschijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, Feelders RA. Quax RA, et al. Nat Rev Endocrinol. 2013 Nov;9(11):670-86. doi: 10.1038/nrendo.2013.183. Epub 2013 Oct 1. Nat Rev Endocrinol. 2013. PMID: 24080732 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information